Ingalls & Snyder LLC Marker Therapeutics, Inc. Transaction History

Ingalls & Snyder LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 27, 2021	SELL	$1.68 - $2.88 $25,872 - $44,352	-15,400 Closed	0 $0
Q4 2020 Jan 27, 2021	SELL	$1.36 - $1.75 $10,472 - $13,475	-7,700 Reduced 33.33%	15,400 $22,000
Q1 2020 Apr 22, 2020	SELL	$1.59 - $3.35 $2,544 - $5,360	-1,600 Reduced 6.48%	23,100 $44,000
Q4 2019 Jan 15, 2020	SELL	$2.68 - $4.85 $152,492 - $275,965	-56,900 Reduced 69.73%	24,700 $71,000
Q3 2019 Oct 16, 2019	SELL	$4.1 - $9.0 $26,239 - $57,600	-6,400 Reduced 7.27%	81,600 $417,000
Q2 2019 Jul 11, 2019	SELL	$5.15 - $7.92 $4,120 - $6,336	-800 Reduced 0.9%	88,000 $697,000
Q4 2018 Jan 24, 2019	BUY	$4.2 - $9.74 $372,960 - $864,912	88,800 New	88,800 $493,000

475K

Ticker MRKR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,599,200
Market Cap $164M
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

Stay updated on Ingalls & Snyder LLC with notifications on news.